(Q34058964)

30 July 2017

1 reference

title

HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles (English)

1 reference

30 July 2017

Beaird SL

1

1 reference

30 July 2017

publication date

1 September 2000

1 reference

Journal of the American Pharmacists Association

30 July 2017

published in

1 reference

30 July 2017

volume

40

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

637-644

1 reference

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Recent advances: the cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Lovastatin and rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Interaction of citrus juices with felodipine and nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Drug-interaction-induced rhabdomyolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Rhabdomyolysis due to interaction of simvastatin with mibefradil

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Potential interaction between warfarin and fluvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Potential warfarin-fluvastatin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1086-5802%2816%2931104-4

7 January 2021

10.1016/S1086-5802(16)31104-4

Identifiers

DOI

0 references

1 reference